assureallc, Author at AssureaLLC

17May

Contract & SLA Checklist for SaaS and AI Vendors in Pharma GxP Environments

May 17, 2026by assureallcin Emerging Technologies

Pharma companies cannot rely on standard commercial SaaS contracts alone when regulated systems, GxP data, or AI-enabled workflows are involved. In regulated environments, contracts and SLAs help define operational oversight expectations that support validation, data integrity, cybersecurity, supplier governance, and inspection readiness. Most commercial agreements are designed around uptime and commercial liability. Pharma and biotech

11May

What Oversight Drift Looks Like in Modern Pharma Digital Systems

May 11, 2026by assureallcin Computer System Validation

In pharma and biotech, digital systems rarely stay the same after they go live. Workflows change, users increase, integrations are added, suppliers release updates, and the system becomes part of a larger operational environment. The real challenge is that oversight does not always evolve at the same pace. A system may still be validated, documented,

09Apr

AI Governance Frameworks That Work for Pharma

April 9, 2026by assureallcin Emerging Technologies

An AI governance framework for pharma works only when it goes beyond policy. It needs to connect each AI use case to a clear intended use, a defined risk tier, required controls, and ongoing monitoring. That is what makes the framework usable in practice and defensible in audit. If those links are missing, the framework

29Mar

How to Audit IT Infrastructure in GxP Environments

March 29, 2026by assureallcin Information Technology

Auditing IT infrastructure in a GxP environment means checking whether the technical foundation behind regulated systems is controlled, supportable, and appropriate for its intended use. The audit should not stop at servers or network diagrams. It should test whether access, changes, backups, monitoring, and supporting services are managed in a way that protects system reliability

26Mar

SaaS and Cloud Validation in Life Sciences: What Makes It Different and What Inspectors Really Ask

March 26, 2026by assureallcin Computer System Validation

SaaS and cloud validation is different because the regulated company no longer controls the full technical stack, but it still owns intended use, oversight, data integrity, access, and compliance. When a system is vendor-hosted, the validation work does not go away. It shifts. Instead of focusing mainly on internally managed infrastructure, the company has to

04Dec

Validating Interfaces & Data Flows: Essential for Digital Validation in Life Sciences

December 4, 2025by assureallcin Computer System Validation

In today’s digital biotech environment, labs and manufacturing sites rely on a complex network of interconnected systems: LIMS, QMS, MES, ERP, CDS, eBMRs, data historians, and analytics platforms. While each system may be validated independently, the movement of data between them is where the highest risk now lives. Regulators increasingly expect organizations to demonstrate end-to-end

13Nov

Case Study: MSAT Staffing to Support a U.S.–to–EU Pharma Technology Transfer

November 13, 2025by assureallcin Staffing

Background: A Late-Stage Biopharma Preparing for EU Commercialization A mid-sized U.S.-based biopharmaceutical company was preparing to commercialize its first biologic product in the European Union. As part of its global expansion strategy, the company initiated a technology transfer from its U.S. clinical manufacturing facility to a commercial EU site (located in Ireland). While the company

06Nov

Case Study: AI-Driven Supplier Audit Data Summarization

November 6, 2025by assureallcin Emerging Technologies

Turning Supplier Audit Files into Actionable Insights for a Mid-Size Biotech Introduction A mid-size biotech organization with approximately 600 employees and a single GMP manufacturing site faced a common challenge: hundreds of supplier audit reports, self-assessment questionnaires, and CAPA summaries stored across multiple folders, but no easy way to extract trends or prioritize risks. The

16Oct

Case Study: Accelerating a Biotech Site Expansion with Assurea’s Staffing Expertise

October 16, 2025by assureallcin Staffing

Client: A Biotech CompanyIndustry: Life Sciences / Pharmaceutical ManufacturingSize: 150–200 employeesEngagement Type: Full-service contract staffing partnershipPartner: Assurea Background A rapidly growing biotech company specializing in cell and gene therapy recently secured Series C funding to expand its manufacturing capacity. The organization planned to establish a new biomanufacturing site in New Jersey, aimed at scaling production

06Oct

From CSV to CSA: What FDA’s New Guidance Means for Regulated Software

October 6, 2025by assureallcin Computer System Validation

The FDA has finalized its Computer Software Assurance for Production and Quality System Software guidance — a long-awaited update that signals the end of “business as usual” for software validation in regulated industries. For decades, Computerized System Validation (CSV) has been the framework life sciences companies relied on. While it provided structure, CSV often created

Categories